Reimbursement is allowed for CKD patients on hemodialysis treatment with Hb ≤ 11 g/dL and serum ferritin < 200 ng/mL or TSAT < 20%, and for CKD patients on peritoneal dialysis with Hb ≤ 11 g/dL and serum ferritin < 100 ng/mL or TSAT < 20%. This evidence concerns the gene GSTM1 and chronic kidney disease.